InterVenn Biosciences
InterVenn, a California-based medical firm, leverages glycoproteomics to develop transformative healthcare solutions.
InterVenn, a California-based medical firm, leverages glycoproteomics to develop transformative healthcare solutions.
InterVenn Biosciences, founded in South San Francisco, California, is a pioneering life science company focused on unlocking the value of glycoproteomics for transformational healthcare solutions. Their core mission is to leverage glycosylated proteins, which drive protein function, to develop advanced medical insights and treatments. InterVenn's GlycoVision™ platform utilizes AI to enhance the speed, scope, and scale of glycoproteomics, enabling breakthroughs in biomarker discovery, disease detection and progression, therapeutic response, and monitoring.
Notable affiliated individuals include founders and key scientific advisors who are leaders in biotechnology and AI. The company has attracted significant investments from prominent venture capital firms, underscoring its potential impact. Key achievements include the development of their proprietary GlycoVision™ platform and its application in precision medicine. InterVenn Biosciences is poised to revolutionize healthcare by providing unprecedented insights into human biology through high-resolution glycoproteomics.
Companies similar to InterVenn Biosciences include Vevo Therapeutics, Noetik, Envisagenics and Entwine Bio.
InterVenn Biosciences was founded in 2017.
InterVenn Biosciences' headquarters is located in South San Francisco, CA, US.
InterVenn Biosciences' most recent funding round was for $201M (USD) in August 2021.
As of Aug 2, 2021, InterVenn Biosciences has disclosed funding of $278.1M (USD). Undisclosed round amounts are excluded.
InterVenn Biosciences has 155 employees as of Feb 5, 2024.
Entwine Bio
entwine.bio
